Education
About Us
Working with TipRanks
Follow Us
Nanologica AB (SE:NICA)
:NICA
NICA Stock Chart & Stats
kr0.74
kr0.03(1.43%)
At close: 4:00 PM EST
kr0.74
kr0.03(1.43%)
Day’s Range― - ―
52-Week Rangekr0.38 - kr2.07
Previous CloseN/A
Volume105.00
Average Volume (3M)111.94K
Market Cap
kr36.14M
Enterprise Valuekr41.09M
Total Cash (Recent Filing)kr13.97M
Total Debt (Recent Filing)kr19.71M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 26, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding88,357,230
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.22
Price to Sales (P/S)6.20
P/FCF Ratio-1.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TractionSustained top-line growth indicates improving commercial traction for Nanologica's nanoparticle platform. Durable revenue expansion from collaborations suggests increasing market acceptance and strengthens the case for recurring milestone and royalty income that can support longer-term R&D and partnerships.
Manageable LeverageRelatively low reported leverage gives the company more financial flexibility versus highly leveraged peers. Manageable debt levels reduce immediate solvency risk, preserving capacity to fund development programs, negotiate partnership terms, or access incremental capital without acute refinancing pressure.
Collaboration/licensing Business ModelA partnership and licensing-led model is capital-light and aligns incentives with pharma partners, offering milestone and royalty upside. This structure spreads development risk, can deliver non-dilutive revenue, and facilitates commercial scale via partner sales forces rather than building expensive in-house commercialization.
Bears Say
Negative Gross Profit And Large Net LossesNegative gross profit and persistent net losses show the core technology has not yet generated sustainable margins. This undermines operating leverage and return metrics, erodes equity over time, and means future growth must translate into meaningful gross-profit recovery to create a durable, self-funding business.
Heavy Cash Burn And Worsening Free Cash FlowDeeply negative operating and free cash flows raise ongoing financing risk and the likelihood of dilution or restrictive financing terms. Persistent cash burn limits runway for R&D or commercialization investment and makes the company dependent on external capital access over the medium term.
Small Operating ScaleA very small headcount constrains internal capacity to manage complex drug-delivery projects, regulatory filings, and larger partnerships. Heavy reliance on partners and contractors increases execution risk and may slow productization, scale-up, and oversight as collaborations move toward commercial stages.
Nanologica AB News
NICA FAQ
What was Nanologica AB’s price range in the past 12 months?
Nanologica AB lowest stock price was kr0.38 and its highest was kr2.07 in the past 12 months.
What is Nanologica AB’s market cap?
Nanologica AB’s market cap is kr36.14M.
When is Nanologica AB’s upcoming earnings report date?
Nanologica AB’s upcoming earnings report date is Feb 26, 2026 which is in 3 days.
How were Nanologica AB’s earnings last quarter?
Nanologica AB released its earnings results on Oct 23, 2025. The company reported -kr0.1 earnings per share for the quarter, beating the consensus estimate of -kr0.2 by kr0.1.
Is Nanologica AB overvalued?
According to Wall Street analysts Nanologica AB’s price is currently Overvalued.
Does Nanologica AB pay dividends?
Nanologica AB does not currently pay dividends.
What is Nanologica AB’s EPS estimate?
Nanologica AB’s EPS estimate is -0.1.
How many shares outstanding does Nanologica AB have?
Nanologica AB has 88,357,230 shares outstanding.
What happened to Nanologica AB’s price movement after its last earnings report?
Nanologica AB reported an EPS of -kr0.1 in its last earnings report, beating expectations of -kr0.2. Following the earnings report the stock price went down -7.746%.
Which hedge fund is a major shareholder of Nanologica AB?
Currently, no hedge funds are holding shares in SE:NICA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanologica AB
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.
Technical Analysis
Alzinova AB
―
Biosergen AB
―
Biovica International AB Class B
―
NextCell Pharma AB
―
Spago Nanomedical AB
―